Related Experiment Videos
Long-term benefit of dobutamine in patients with congestive cardiomyopathy
Insights
Short-term dobutamine infusions improved systolic time intervals and echocardiogram measures in heart failure patients, with benefits lasting months. This suggests dobutamine is effective for chronic congestive heart failure therapy.
Area of Science:
- Cardiology
- Pharmacology
- Heart Failure Research
Background:
- Congestive cardiomyopathy significantly impairs cardiac function.
- Effective therapeutic strategies for chronic heart failure are crucial.
Purpose of the Study:
- To evaluate the long-term effects of a three-day intravenous dobutamine infusion on left ventricular function in patients with congestive cardiomyopathy.
- To determine if dobutamine therapy improves functional class and non-invasive cardiac measurements.
Main Methods:
- 38 patients with congestive cardiomyopathy received intravenous dobutamine for three days.
- Serial assessments included functional class, systolic time intervals (PEP/LVET), and echocardiogram (% delta D).
- Measurements were taken during and up to 10 months after dobutamine discontinuation.
Main Results:
- Significant decline in average PEP/LVET observed at multiple time points up to 10 months post-infusion (p < 0.001).
- Sustained improvement in PEP/LVET and % delta D in a majority of patients weeks and months after treatment.
- Patients with thicker left ventricular walls (>0.5 cm/M2) were more likely to respond positively.
Conclusions:
- A three-day dobutamine infusion demonstrated prolonged positive effects on left ventricular function in heart failure patients.
- Dobutamine shows potential as a therapeutic agent for managing chronic congestive heart failure.
- Further research is needed to elucidate the mechanism behind these sustained improvements.
Abstract:
Dobutamine was given intravenously for three days to 38 patients with congestive cardiomyopathy. The patients were followed by serial determinations of functional class and by non-invasive measurements of left ventricular function-systolic time intervals (PEP/LVET) and echocardiogram (% delta D). The average PEP/LVET declined significantly (p < 0.001) at three days, four and nine weeks, and at 10 months after the discontinuation of dobutamine infusion. Also, 67% (20 of 30) of patients had improvement of the PEP/LVET by greater than -0.04 at seven days. Even two and six months after dobutamine, 58% (15 of 26) and 39% (seven of 18) were improved. Similarly, the % delta D was improved by at least 2% in 60% (18 of 30) at seven days and 55% (16 of 29) at four weeks. At two and six months, 50% (14 of 28) and 42% (10 of 24) were improved. Those patients who did not improve their FC were more likely (five of nine) to have left ventricular free wall thickness (by echocardiogram) less than 0.5 cm./M2. Those who responded usually (22 of 29) had a ventricular wall thickness greater than 0.5 cm./M2. Although the mechanism of the prolonged improvement after a three day infusion of dobutamine is not understood, this study suggests that dobutamine has a role in the therapy of chronic congestive heart failure.